Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor von Belum, V.R, Benhuri, B, Postow, M.A, Hellmann, M.D, Lesokhin, A.M, Segal, N.H, Motzer, R.J, Wu, S, Busam, K.J, Wolchok, J.D, Lacouture, M.E

Volltext

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy von Naidoo, Jarushka, Wang, Xuan, Woo, Kaitlin M, Iyriboz, Tunc, Halpenny, Darragh, Cunningham, Jane, Chaft, Jamie E, Segal, Neil H, Callahan, Margaret K, Lesokhin, Alexander M, Rosenberg, Jonathan, Voss, Martin H, Rudin, Charles M, Rizvi, Hira, Hou, Xue, Rodriguez, Katherine, Albano, Melanie, Gordon, Ruth-Ann, Leduc, Charles, Rekhtman, Natasha, Harris, Bianca, Menzies, Alexander M, Guminski, Alexander D, Carlino, Matteo S, Kong, Benjamin Y, Wolchok, Jedd D, Postow, Michael A, Long, Georgina V, Hellmann, Matthew D

Volltext

Nivolumab plus Ipilimumab in Advanced Melanoma von Wolchok, Jedd D, Kluger, Harriet, Callahan, Margaret K, Postow, Michael A, Rizvi, Naiyer A, Lesokhin, Alexander M, Segal, Neil H, Ariyan, Charlotte E, Gordon, Ruth-Ann, Reed, Kathleen, Burke, Matthew M, Caldwell, Anne, Kronenberg, Stephanie A, Agunwamba, Blessing U, Zhang, Xiaoling, Lowy, Israel, Inzunza, Hector David, Feely, William, Horak, Christine E, Hong, Quan, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok, Sznol, Mario

Volltext

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma von Martin, Thomas, Baz, Rachid, Benson, Don M., Lendvai, Nikoletta, Wolf, Jeffrey, Munster, Pamela, Lesokhin, Alexander M., Wack, Claudine, Charpentier, Eric, Campana, Frank, Vij, Ravi

Volltext

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study von Lesokhin, Alexander M, Ansell, Stephen M, Armand, Philippe, Scott, Emma C, Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M, Cohen, Adam D, Schuster, Stephen J, Lebovic, Daniel, Dhodapkar, Madhav, Avigan, David, Chapuy, Bjoern, Ligon, Azra H, Freeman, Gordon J, Rodig, Scott J, Cattry, Deepika, Zhu, Lili, Grosso, Joseph F, Bradley Garelik, M Brigid, Shipp, Margaret A, Borrello, Ivan, Timmerman, John

Volltext

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma von Ansell, Stephen M, Lesokhin, Alexander M, Borrello, Ivan, Halwani, Ahmad, Scott, Emma C, Gutierrez, Martin, Schuster, Stephen J, Millenson, Michael M, Cattry, Deepika, Freeman, Gordon J, Rodig, Scott J, Chapuy, Bjoern, Ligon, Azra H, Zhu, Lili, Grosso, Joseph F, Kim, Su Young, Timmerman, John M, Shipp, Margaret A, Armand, Philippe

Volltext

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action von Wudhikarn, Kitsada, Wills, Beatriz, Lesokhin, Alexander M.

Volltext

Soluble B‐cell maturation antigen in multiple myeloma von Costa, Bruno Almeida, Ortiz, Ricardo J., Lesokhin, Alexander M., Richter, Joshua

Volltext

Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma? von Maclachlan, Kylee H., Lesokhin, Alexander M.

Volltext

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial von Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.

Volltext

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies von Ansell, Stephen M., Maris, Michael B., Lesokhin, Alexander M., Chen, Robert W., Flinn, Ian W., Sawas, Ahmed, Minden, Mark D., Villa, Diego, Percival, Mary-Elizabeth M., Advani, Anjali S., Foran, James M., Horwitz, Steven M., Mei, Matthew G., Zain, Jasmine, Savage, Kerry J., Querfeld, Christiane, Akilov, Oleg E., Johnson, Lisa D. S., Catalano, Tina, Petrova, Penka S., Uger, Robert A., Sievers, Eric L., Milea, Anca, Roberge, Kathleen, Shou, Yaping, O'Connor, Owen A.

Volltext

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies von Armand, Philippe, Lesokhin, Alexander, Borrello, Ivan, Timmerman, John, Gutierrez, Martin, Zhu, Lili, Popa McKiver, Mihaela, Ansell, Stephen M.

Volltext

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma von Postow, Michael A, Callahan, Margaret K, Barker, Christopher A, Yamada, Yoshiya, Yuan, Jianda, Kitano, Shigehisa, Mu, Zhenyu, Rasalan, Teresa, Adamow, Matthew, Ritter, Erika, Sedrak, Christine, Jungbluth, Achim A, Chua, Ramon, Yang, Arvin S, Roman, Ruth-Ann, Rosner, Samuel, Benson, Brenna, Allison, James P, Lesokhin, Alexander M, Gnjatic, Sacha, Wolchok, Jedd D

Volltext

Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma von Lesokhin, Alexander M, Bal, Susan, Badros, Ashraf Z

Volltext

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders von Shah, Urvi A., Parikh, Richa, Castro, Francesca, Bellone, Matteo, Lesokhin, Alexander M.

Volltext

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel von Raje, Noopur, Anderson, Kenneth, Einsele, Hermann, Efebera, Yvonne, Gay, Francesca, Hammond, Sarah P., Lesokhin, Alexander M., Lonial, Sagar, Ludwig, Heinz, Moreau, Philippe, Patel, Krina, Ramasamy, Karthik, Mateos, Maria-Victoria

Volltext

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 von Naidoo, Jarushka, Schindler, Katja, Querfeld, Christiane, Busam, Klaus, Cunningham, Jane, Page, David B, Postow, Michael A, Weinstein, Alyona, Lucas, Anna Skripnik, Ciccolini, Kathryn T, Quigley, Elizabeth A, Lesokhin, Alexander M, Paik, Paul K, Chaft, Jamie E, Segal, Neil H, D'Angelo, Sandra P, Dickson, Mark A, Wolchok, Jedd D, Lacouture, Mario E

Volltext

Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment von LESOKHIN, Alexander M, HOHL, Tobias M, MERGHOUB, Taha, WOLCHOK, Jedd D, KITANO, Shigehisa, CORTEZ, Czrina, HIRSCHHORN-CYMERMAN, Daniel, AVOGADRI, Francesca, RIZZUTO, Gabrielle A, LAZARUS, John J, PAME, Eric G, HOUGHTON, Alan N

Volltext

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors von Kim, Tae Won, Burris, Howard A, de Miguel Luken, Maria J, Pishvaian, Michael J, Bang, Yung-Jue, Gordon, Michael, Awada, Ahmad, Camidge, D Ross, Hodi, F Stephen, McArthur, Grant A, Miller, Wilson H, Cervantes, Andres, Chow, Laura Q, Lesokhin, Alexander M, Rutten, Annemie, Sznol, Mario, Rishipathak, Deepali, Chen, Shang-Chiung, Stefanich, Eric, Pourmohamad, Tony, Anderson, Maria, Kim, Jeong, Huseni, Mahrukh, Rhee, Ina, Siu, Lillian L

Volltext

Harnessing the immune system for cancer therapy von Smith, Eric L, Zamarin, Dmitriy, Lesokhin, Alexander M

Volltext